By Colin Kellaher
Merck & Co. on Friday said the European Commission approved expanded use of its blockbuster cancer drug Keytruda in combination with chemotherapy for the first-line treatment of certain patients with locally recurrent unresectable or metastatic triple-negative breast cancer.
The Kenilworth, N.J., drugmaker said the approval, its first for Keytruda in Europe in a breast-cancer setting, covers the treatment of adults whose tumors express PD-L1 with a combined positive score of at least 10 and who haven't received prior chemotherapy for metastatic disease.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in numerous indications across a range of cancers around the world.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires